ASCO 2026 preview – Pumitamig looks similar to ivonescimab again
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
Pfizer targets VEGF bispecific white space
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
EHA 2026 preview – a Monumental boost to J&J’s Talvey hopes
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
MacroGenics changes its tune on Linnet
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Merck makes a new move in Astra battle
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Crossover hits Compass
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
Astra goes subcutaneous in its Merck race
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
